Prostate Cancer
MDV3100 for Patients Undergoing Prostatectomy for Prostate Cancer
A Randomized, Open-Label, Phase 2 Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
| Status | Conditions | Phase | Study ID |
| Closed | Prostate Cancer | Phase II | NCT01547299 |
Summary
The purpose of this study is to determine if MDV3100 is an effective therapy in treating localized prostate cancer prior to prostatectomy.
|
|
Eligibility Criteria (must meet the following to participate in this study)
- Willing to provide informed consent
- 18 years of age or older
- Histologically confirmed adenocarcinoma of the prostate
- Must be a candidate for radical prostatectomy and considered surgically resectable
Exclusions (conditions that would prevent participation in this study)
- Stage T4 prostate cancer by clinical or radiologic evaluation
- Treatment with an investigational agent within 4 weeks prior to randomization
- Received therapy for for other neoplastic disorders within 5 years
- Hypogonadism or severe androgen deficiency
Last Updated
March 13, 2013See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
Join Us On